Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialy… Read more
Akebia Therapeutics Inc - Asset Resilience Ratio
Akebia Therapeutics Inc (AX9) has an Asset Resilience Ratio of 0.00% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2021)
This chart shows how Akebia Therapeutics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Akebia Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Akebia Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Akebia Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Akebia Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
High Sierra Technologies Inc
PINK:HSTI |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
Annual Asset Resilience Ratio for Akebia Therapeutics Inc (2015–2021)
The table below shows the annual Asset Resilience Ratio data for Akebia Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | €0.00 | €525.55 Million | -- |
| 2020-12-31 | 6.21% | €39.99 Million | €644.14 Million | +6.18pp |
| 2019-12-31 | 0.03% | €245.00K | €771.20 Million | -21.74pp |
| 2018-12-31 | 21.77% | €217.00 Million | €996.54 Million | -46.21pp |
| 2017-12-31 | 67.99% | €247.64 Million | €364.25 Million | +43.67pp |
| 2016-12-31 | 24.32% | €73.01 Million | €300.22 Million | -37.72pp |
| 2015-12-31 | 62.04% | €88.68 Million | €142.94 Million | -- |